Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
New England Journal of Medicine · 27.03.2025 · 392 (12) · 1189-1202
DOI: 10.1056/nejmoa2410858 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 27.03.2025. Verfasst von Komal L Jhaveri und 29 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York. Hauptthemen laut MEDLINE: Aminopyridines, Antineoplastic Combined Chemotherapy Protocols, Benzimidazoles, Breast Neoplasms. Die Arbeit wurde bisher 232-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Eli Lilly and Company.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York.
- University Hospitals Leuven, Leuven, Belgium.
- Hospital María Curie, Buenos Aires.
- Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
- Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Brussels.
ORCID-Profile: Lisa A Carey, Giuseppe Curigliano, Joohyuk Sohn, François-Clément Bidard
Förderung
- NCI NIH HHS
- Eli Lilly and Company
Zitieren
APA
Jhaveri, K. L., Neven, P., Casalnuovo, M. L., Kim, S. B., Tokunaga, E., Aftimos, P., Saura, C., O'Shaughnessy, J., Harbeck, N., Carey, L. A., Curigliano, G., Llombart-Cussac, A., Lim, E., García Tinoco, M. L., Sohn, J., Mattar, A., Zhang, Q., Huang, C. S., Hung, C. C., …, & EMBER-3 Study Group (2025). Imlunestrant with or without Abemaciclib in Advanced Breast Cancer. New England Journal of Medicine, 392(12), 1189-1202. https://doi.org/10.1056/nejmoa2410858
Vancouver
Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, et al. Imlunestrant with or without Abemaciclib in Advanced Breast Cancer. New England Journal of Medicine. 2025;392(12):1189-1202. doi:10.1056/nejmoa2410858
BibTeX
@article{Jhaveri2025,
author = {Jhaveri, Komal L and Neven, Patrick and Casalnuovo, Monica Lis and Kim, Sung-Bae and Tokunaga, Eriko and Aftimos, Philippe and Saura, Cristina and O'Shaughnessy, Joyce and Harbeck, Nadia and Carey, Lisa A and Curigliano, Giuseppe and Llombart-Cussac, Antonio and Lim, Elgene and García Tinoco, María de la Luz and Sohn, Joohyuk and Mattar, André and Zhang, Qingyuan and Huang, Chiun-Sheng and Hung, Chih-Chiang and Martinez Rodriguez, Jorge Luis and Ruíz Borrego, Manuel and Nakamura, Rikiya and Pradhan, Kamnesh R and Cramer von Laue, Christoph and Barrett, Emily and Cao, Shanshan and Wang, Xuejing Aimee and Smyth, Lillian M and Bidard, François-Clément and EMBER-3 Study Group, EMBER-3 Study Group},
title = {Imlunestrant with or without Abemaciclib in Advanced Breast Cancer},
journal = {New England Journal of Medicine},
year = {2025},
volume = {392},
number = {12},
pages = {1189--1202},
doi = {10.1056/nejmoa2410858}
}
EUVIMED